Article Figures & Data
Tables
Radiopharmaceutical Administered activity MBq (mCi) Organ receiving the largest dose mGy/MBq (rad/mCi) Effective dose equivalent mSv/MBq (rem/mCi) 111In-pentetreotide spleen 222 0.665 0.117 (6) (2.46) (0.433) -
Data adapted from (11).
-
In this issue
Jump to section
- Article
- PART I: PURPOSE
- PART II: BACKGROUND INFORMATION AND DEFINITIONS
- PART III: COMMON INDICATIONS
- PART IV: PROCEDURE
- PART V: ISSUES REQUIRING FURTHER CLARIFICATION
- PART VI: CONCISE BIBLIOGRAPHY
- PART VII: DISCLAIMER
- PART VIII: LAST HOUSE OF DELEGATES APPROVAL DATE
- PART IX: NEXT ANTICIPATED APPROVAL DATE
- Acknowledgments
- Footnotes
- Figures & Data
- Info & Metrics
Related Articles
Cited By...
- Long-Acting Somatostatin Analog Therapy Differentially Alters 68Ga-DOTATATE Uptake in Normal Tissues Compared with Primary Tumors and Metastatic Lesions
- Potential value of EUS in pancreatic surveillance of VHL patients
- Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors
- GEP-NETS update: Functional localisation and scintigraphy in neuroendocrine tumours of the gastrointestinal tract and pancreas (GEP-NETs)
- Frequency and characterization of gastro-entero-pancreatic neuroendocrine tumor patients with high-grade of uptake at somatostatin receptor scintigraphy
- Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours
- The Role of 68Ga-DOTATATE PET in Patients with Neuroendocrine Tumors and Negative or Equivocal Findings on 111In-DTPA-Octreotide Scintigraphy
- From the authors:
- Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors
- Tumor Receptor Imaging
- Utility of Radiolabeled Somatostatin Receptor Analogues for Staging/Restaging and Treatment of Somatostatin Receptor-Positive Pediatric Tumors
- Improved Staging of Patients With Carcinoid and Islet Cell Tumors With 18F-Dihydroxy-Phenyl-Alanine and 11C-5-Hydroxy-Tryptophan Positron Emission Tomography
- 68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT
- Gluc-Lys([18F]FP)-TOCA PET in Patients with SSTR-Positive Tumors: Biodistribution and Diagnostic Evaluation Compared with [111In]DTPA-Octreotide
- Synergistic effects of light-emitting probes and peptides for targeting and monitoring integrin expression
- Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies
- Molecular Imaging as In Vivo Molecular Pathology for Gastroenteropancreatic Neuroendocrine Tumors: Implications for Follow-Up After Therapy
- MIBG and Somatostatin Receptor Analogs in Children: Current Concepts on Diagnostic and Therapeutic Use
- An Intrapatient Comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-Octreotide for Diagnosis of Somatostatin Receptor-Expressing Tumors